Key Facts Surrounding This News Item
- EXAS had returned +4.80% year-to-date leading up to today’s news, versus a 0.00% return from the benchmark S&P 500 during the same period.
More Info About Exact Sciences Corporation (EXAS)
Exact Sciences is a molecular diagnostics company focused on gastrointestinal cancers. The company develops the Cologuard, a non-invasive stool-based DNA colorectal cancer screening test that is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. The company was founded in 1995 and is based in Madison, Wisconsin. View our full EXAS ticker page with ratings, news, and more.